This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Tipranks - Sat Jun 6, 11:56AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY), Cytokinetics (CYTK) and Doximity (DOCS) with bullish sentiments.

Claim 55% Off TipRanks

Eli Lilly & Co (LLY)

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co today and set a price target of $1500.00. The company’s shares closed last Friday at $1150.30.

According to TipRanks.com, Meacham is a 5-star analyst with an average return of 9.7% and a 55.5% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Protagonist Therapeutics, and Kiniksa Pharmaceuticals. ;'>

Eli Lilly & Co has an analyst consensus of Strong Buy, with a price target consensus of $1267.57, implying a 10.9% upside from current levels. In a report issued on May 21, BMO Capital also maintained a Buy rating on the stock with a $1300.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Cytokinetics (CYTK)

In a report released today, Tessa Romero from J.P. Morgan maintained a Buy rating on Cytokinetics, with a price target of $97.00. The company’s shares closed last Friday at $71.94, close to its 52-week high of $75.71.

According to TipRanks.com, Romero is a 4-star analyst with an average return of 15.9% and a 50.0% success rate. Romero covers the Healthcare sector, focusing on stocks such as Neumora Therapeutics, Inc., EyePoint Pharmaceuticals, and Rocket Pharmaceuticals. ;'>

Cytokinetics has an analyst consensus of Strong Buy, with a price target consensus of $100.35, implying a 37.8% upside from current levels. In a report issued on May 28, TipRanks – Google also upgraded the stock to Buy with a $86.00 price target.

Doximity (DOCS)

Bank of America Securities analyst Allen Lutz maintained a Buy rating on Doximity today and set a price target of $38.00. The company’s shares closed last Friday at $20.57.

According to TipRanks.com, Lutz is a 5-star analyst with an average return of 10.7% and a 64.0% success rate. Lutz covers the Healthcare sector, focusing on stocks such as Guardian Pharmacy Services, Inc. Class A, Definitive Healthcare Corp, and Hims & Hers Health. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Doximity with a $26.28 average price target, a 25.1% upside from current levels. In a report issued on May 30, TipRanks – OpenAI also upgraded the stock to Buy with a $24.00 price target.

Read More on LLY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).